Galafold (migalastat capsules) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data
• Medication is prescribed by or in consultation with a geneticist, nephrologist, or a physician who specializes in the treatment of Fabry disease

Approval duration

1 year